Xcout Intel
リプロセル competitors & alternatives
The 12 closest competitors and alternatives to リプロセル among biotech companies — ranked by similarity to what リプロセル actually does, not by market-cap band.
Subscribe to see リプロセル’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About リプロセル
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
リプロセル at a glance
リプロセル is a biotech company headquartered in Yokohama, Japan. It is publicly listed (4978) with a market capitalisation of $94.1M. Xcout tracks 9 named people at リプロセル, including Chikafumi Yokoyama (Chief Executive Officer, REPROCELL, Inc.).
リプロセル leadership
- Chikafumi YokoyamaChief Executive Officer, REPROCELL, Inc.
- Daisuke UsuiCOO, REPROCELL Inc. CEO, Bioserve Biotechnologies India, Pvt. Ltd.
- Karen BinghamCOO, REPROCELL Europe Ltd.
- David BuntonCEO, REPROCELL Europe Ltd.
- Rama ModaliCEO, REPROCELL USA Inc.
- Hiromitsu NakauchiProfessor and Director, Center for Stem Cell and Regenerative Medicine, Institute of Medical Science, The University of Tokyo
3 more named people on record for リプロセル, with roles, board committees and tenure — see the full roster →
Top 12 リプロセル competitors
Ranked by semantic similarity — how close each company is to リプロセル by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
Accelerated Biosciences provides human trophoblast stem cell (hTSC) platforms, intellectual property, protocols, and starting materials to biopharma companies and research institutions. The company aims to support partners in developing novel regenerative medicine products, cell therapies, and immunotherapies.
Similar biotech company
InSphero provides 3D in vitro cell culture models, microplates, organ-on-a-chip platforms, and related services for drug discovery and safety testing. The company serves pharmaceutical, biotechnology, and research organizations seeking non-animal testing alternatives to evaluate drug efficacy, liver safety, oncology, and other complex diseases.
Biotechnology
Axol Bioscience is a leading provider of iPSC-derived cells and related services, supporting neuroscience, ophthalmology, and cardiotoxicity drug discovery with advanced human disease models.
Biotechnology
Deep Cell Industries Inc. provides an AI-integrated platform called REM-I that combines label-free imaging, deep learning, and cell enrichment for single-cell morpholomic analysis. The company serves researchers and organizations in oncology, drug discovery, cell and gene therapy, and related life science fields by enabling high-resolution profiling and sorting of viable cells.
Similar biotech company
Biocytogen provides fully human antibody discovery services and preclinical contract research organization (CRO) services. The company offers genetically engineered animal models, cell lines, gene editing services, and in vivo and in vitro pharmacology studies to support biopharmaceutical research and drug development.
Similar biotech company
Hubrecht Organoid Technology (HUB) develops patented patient-derived organoid technology from healthy and diseased tissues to predict patient responses to treatments. The company functions as a contract research organization (CRO), offering drug discovery services, custom model and assay development, clinical trials in a dish, and licensing programs for pharmaceutical and research applications.
Similar biotech company
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Biotechnology
Shanghai Model Organisms Center, Inc. (SMOC) is a prominent Chinese enterprise dedicated to the research and development of genetically engineered animal models. The company offers a broad spectrum of specialized rodent models, encompassing disease-specific, humanized, immunodeficient, tool, and fluorescent reporter strains of both mice and rats. Furthermore, SMOC produces custom cellular products, including fluorescently labeled, primary, and humanized cell lines. Beyond its core product offerings, SMOC delivers a comprehensive suite of support services. These include personalized model generation, animal husbandry and breeding programs, in-depth phenotypic analysis, and critical drug screening and evaluation services for preclinical research. Established in 2000, SMOC maintains its primary operations and corporate headquarters in Shanghai, China.
Similar biotech company
BICO provides lab automation software, instruments, biomaterials, and liquid handling solutions for life science research, drug discovery, and tissue engineering. The company serves pharmaceutical companies, biotechnology firms, and academic institutions by automating laboratory workflows and providing 3D bioprinting and imaging technologies.
Biotechnology
iOrganBio is a biotechnology company founded in 2024 that develops AI-powered platforms for the precision engineering and manufacturing of human cells and organoids. The company's CellForge platform aims to create reproducible human cell models for research applications, including cardiac disease studies and biological simulation.
Biotechnology
Organoid Therapeutics, Inc. is a biotechnology contract research organization (CRO) that provides human brain tissue models, neuronal phenotyping, drug screening, and machine learning-based analytical services. The company serves pharmaceutical, biotech, and academic researchers by conducting pre-clinical research and translational studies to evaluate drug efficacy, neurotoxicity, and neurological disease models.
Similar biotech company
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of リプロセル and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for リプロセルand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →